Published on March 20th, 2015 | by Daily Station Team
Revenue Growth in Single Digits for AbbVie (NYSE:ABBV), 4th Quarter Estimates
Industry experts are of the opinion that the figures which will emerge from the fourth quarterly reports of 2014 due to be released by AbbVie (NYSE:ABBV) will show growth figures in both the revenue side of the business, and the earnings factor of the financial statements, but in single-digits only. This is a good enough result for the company operating in the pharmaceutical industry, however, the AbbVie (NYSE:ABBV) seems to have expected more out of the last whole year.
According to company estimates, the expected growth figure was much more than the growth figure that has been predicted for the year 2015. However, industry experts are of the opinion that such a figure may not, now, materialize. For the fourth quarter of 2014, AbbVie (NYSE:ABBV) is expected to have garnered a total revenue figure of $5.34 billion, which is a figure up by 4.4% from that the company put out during the same period of time year over year (YoY).
Also, the earnings figure is also expected to have risen in the fourth quarter of 2014 for the company, by 85 cents for every share authorized by the company at the New York Stock Exchange. This figure is up by 4.3% when put in comparison with the figures that materialized around the same period of time only last year. On a grander scale, the company seems to have outperformed its old self, resulting in the best quarter the company has seen for the past 6 quarters.
Sales figures, in fact, are the best the company has witnessed in the past 7 quarters of operation, which is an excellent progress not many companies within the pharmaceutical industry can claim to have made in the fourth quarter of 2014. Per share earnings for AbbVie (NYSE:ABBV) are expected to be announced at $3.29, which is a figure up by 4.7% than that released for shareholders in the financial statements for 2013. This is a result of increased sales, which stood at a gleaming figure of $19.89 billion, up by 6% than the figure posted in the 2013 financial statements.
Investors have a very positive outlook of AbbVie (NYSE:ABBV), which has again estimated a gleaming growth rate for the year 2015, even if it is still in the single digits. The pharmaceuticals company expects to increase earnings per share to the figure in between $4.25-$4.45. The increasing growth of AbbVie (NYSE:ABBV) is largely due to the Hepatitis C vaccine that the company has entered the market with, offering an alternative to the currently monopolized market for the disease.
JP Morgan estimates that AbbVie (NYSE:ABBV)’s vaccine will be successful in capturing over 20% of the total market for Hepatitis C vaccines this year, where the total market is estimated to value around $15 billion. AbbVie (NYSE:ABBV) stocks operating at the NYSE are currently valued at $64.54 per share. Financial analysts operating within the industry are of the opinion that this stock price will improve dramatically within 2015, reaching a peak value of $74.07. Most of the analysts recommend the stock as a must-make investment.